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Human testicular germ cell tumours express inhibin
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Summary Germ cell development is influenced by activin and inhibin, which are produced by Sertoli cells. Activin also affects differentiation
of mouse embryonal carcinoma cells, which, to a certain extent, resemble the embryonal carcinoma component of germ cell tumours.
Therefore, the expression of inhibin/activin subunits, of activin receptors and of the activin-binding protein follistatin was studied in testicular
germ cell tumours, using RNAase protection assays. Testicular germ cell tumours of adolescents and adults (TGCTs) and spermatocytic
seminomas expressed activin type and type 11 receptors (ActRi and ActRII respectively). Seminomas expressed significantly lower levels of
ActRIIA (P<0.05, Mann-Whitney U-test) and higher levels of ActRIA (P<0.05) and ActRIB (P<0.05) compared with non-seminomas. All
tumours expressed inhibin n-subunit transcripts, which are a prerequisite for activin synthesis. Non-seminomas contained significantly higher
levels of the inhibin PA subunit (P<0.001) compared with seminomas. No activin PC subunit transcripts could be demonstrated by RNAase
protection. Inhibin a-subunit expression was absent in the spermatocytic seminomas, in six out of nine seminomas and in 10 out of 11 non-
seminomas. Follistatin was expressed predominantly in non-seminomas and spermatocytic seminomas. This expression of activin type and
type 11 receptors in combination with expression of inhibin 5-subunits indicates that activin may act as a para- or autocrine factor in the
regulation of growth and differentiation of tumours of human germ cells.
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Testicular tumours account for 1-3% of all malignancies in
Caucasian men, with a peak incidence between 15 and 45 years
of age. In this age group, it is the most frequently encountered
malignancy (Forman and M0ller, 1994). Approximately 95%
ofthe testicular tumours originate from germ cells (Ulbright, 1993;
Forman and M0ller, 1994).
Testicular germ cell tumours ofadolescents and adults (TGCTs)
can be subdivided into two groups of about equal numerical
importance: seminomas and non-seminomas (Ulbright, 1993).
Both these groups develop from intratubular germ cell neoplasia
(carcinoma in-situ or CIS) (Skakkebek et al, 1987), but semi-
nomas and non-seminomas differ in histology and clinical behav-
iour, with the non-seminomas being the more aggressive tumours
(Oosterhuis et al, 1993). Histologically, non-seminomas are classi-
fied as embryonal carcinomas, teratomas, choriocarcinomas and
yolk sac tumours (Mostofi, 1980; Ulbright, 1993). These compo-
nents originate from pluripotent embryonal carcinoma cells
(Andrews et al, 1987) and may occur as the only cell type or may
be intermixed. In contrast to the non-seminomas and the classical
seminoma, the spermatocytic seminoma does not originate from
CIS (Muller et al, 1987; Skakkebaek et al, 1987) but is thought to
arise from neoplastic germ cells at a stage of maturation between
spermatogonia and spermatocytes (Talerman, 1980; Muller et al,
1987; Eble, 1994). Spermatocytic seminoma represents 1-2% of
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all testicular tumours, generally occurs in men over 50 years ofage
and rarely metastasizes (Muiller et al, 1987; Eble, 1994).
Activin and inhibin are members of the transforming growth
factor beta (TGF-1) family of growth and differentiation factors,
which were initially detected in and isolated from gonadal fluids
(de Jong and Sharpe, 1976; Mason et al, 1985; Ling et al, 1986;
Vale et al, 1986). Activin is a homo- or heterodimer oftwo highly
homologous inhibin [3-subunits ([A and [B), which exerts its
action through binding to specific membrane-spanning serine/thre-
onine kinase receptors. The activin type II receptors, either activin
receptor IIA (ActRIIA) or IIB (ActRIIB), bind activin; one of the
activin type I receptors (ActRIA or ActRIB) is then recruited into
the complex and is activated by phosphorylation (Caircamo et al,
1994; Mathews, 1994; Wrana et al, 1994). The biological effects
of activin can be counteracted by the activin-binding protein folli-
statin (Michel et al, 1993) or by inhibin, which is a dimer of an
inhibin ax- and [-subunit (Mather et al, 1992). In the testis, sper-
matogenesis depends on factors produced by Sertoli and Leydig
cells. Inhibin and activin are secreted by Sertoli cells (de Jong,
1988; de Winter et al, 1993), while activin can also be produced by
peritubular myoid cells (de Winter et al, 1994). Germ cells express
activin receptors (Kaipia et al, 1991; de Winter et al, 1992;
Cameron et al, 1994), bind activin and inhibin (Woodruff et al,
1992), and respond to inhibin and activin administration (van
Dissel-Emiliani et al, 1989; Mather et al, 1990).
The human non-seminomatous embryonal carcinoma cell
line Tera-2 (Andrews, 1988) expresses activin type II receptors (de
Jong et al, 1993) and activin type I receptors (RHN van Schaik,
unpublished results). Transcript levels for ActRIIB and follistatin
change dramatically after retinoic acid treatment, suggesting
changes in sensitivity for activin upon cell differentiation. Activin
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itself stimulates the expression ofgrowth and differentiation factor
3 (hGDF-3) in this cell line (Caricasole et al, submitted),
confirming that a functional activin signalling pathway exists in
Tera-2 cells. In mouse embryonal carcinoma cells, activin was
shown to act as a growth factor in undifferentiated P19 cells
(Hashimoto et al, 1990), while retinoic acid-induced differentia-
tion of these cells could be blocked by activin (Hashimoto et al,
1990; van den Eijnden-van Raaij et al, 1991). Furthermore, inhibin
immunoreactivity has been demonstrated in clinical samples of
human TGCTs (de Jong et al, 1990). These observations led us to
investigate whether clinical germ cell tumours express activin
receptors and inhibin/activin subunits. We demonstrated the
expression of activin type I and type II receptors, in combination
with inhibin PA and ,B subunits and follistatin mRNAs.
MATERIALS AND METHODS
Tumour material and RNA isolation
Human testicular tumour material, collected during operation at
the collaborating hospitals, was divided into two representative
portions. One ofthese portions was snap frozen in liquid nitrogen,
while the other portion was fixed in 4% buffered formalin and
embedded in paraffin. Tumours were classified according to the
recommendations ofthe World Health Organization (Mostofi et al,
1987), as described previously (Oosterhuis et al, 1989). In this
study, nine seminomas, 11 non-seminomas and two spermatocytic
seminomas were included. The non-seminoma group consisted of
one pure embryonal carcinoma (EC), two yolk sac tumours (YS),
one mature teratoma (MT), one immature teratoma (IT), three
tumours with two components (one EC/YS and two MT/YS)
and three mixed tumours consisting of EC/IT/MT/YS plus
trophoblastic giant cells in combination with a seminoma compo-
nent. In these mixed tumours, the non-seminoma component could
clearly be distinguished macroscopically from the seminoma
component; only the non-seminoma component was used in this
study. Frozen tissue (-80°C) was pulverized in liquid nitrogen,
followed by RNA isolation using TRIzol reagent (Gibco BRL,
Gaithersburg, MD, USA), according to the manufacturer's
protocol. RNA was dissolved in RNAase-free water and its
concentration and purity were determined by optical density
measurements at 260 and 280 nm. Normal testis RNA was isolated
from tissue provided by the Dr Daniel den Hoed Cancer Center or
was obtained commercially from ClonTech (Palo Alto, CA, USA).
RT-PCR
cDNA was synthesized from total RNA by a random hexamer-
primed reverse transcriptase reaction using AMV reverse tran-
scriptase (Promega, Madison, WI, USA), as described by
Sambrook et al (1989). Oligonucleotide primers (Pharmacia,
Breda, The Netherlands) are based on published human sequences
and are separated by at least one intron in the genomic DNA.
Nucleotides printed in bold represent mismatches to the human
sequence, either to generate restriction sites or because primers
based on the rat/mouse sequence were used as the human sequence
was not known at the time (ActRIIB). Primers used are as follows:
ActRIA, GAGTATGGCA CTATCGAAGG GCT and GAAG-
ATCTTC ACGGCAACAT TTT; ActRIB, ATCGACTTGA
GGGTGCCC and GAATATTTTC ACAGCCACAT CAC;
ActRIIA, CAGGGAACTG GATATCTAGA GAGAACTTC and
TGGTCCTGGG TCTCGAGTAG GAACAAGTAC; ActRIIB,
CGAATTCCGC TGCTGCCCAT TGGAGGC and TGTAA-
GCTTG TGGCCCTCAC CACGACACC; the inhibin a-subunit,
CGAATTCTAG CAGGGCCAGG TGAGCT and TGTAA-
GCTTG TGGCTGGGAA AAGGAT; PA-subunit, TTGCTT-
TGGC TGAGAGGAT and GCCCTTCTTT TTCCCTTCC;
fB-subunit, CGAATTCATC AGCTTCGCCG AGAC and
TGTAAAGCTT GCACTGTCAG GCGCAGCCGC; [C-subunit,
CTTGGACAAG CTGCACCTC (gift from Dr G Hotten,
BioPharm, Germany) and TAGAAGCTTC TGTAGGGGCG
TGTTTC; follistatin, CGAATTCCGA ATGAACAAGA AGAAC
and TGTAAGCTTC TCCCAACCTT GAAATCCC. Actin-
primers (AAGAATTCCT ATGTGGGCGA CGAG and
TAGAAGCTTT TGCGGTGGAC GATGGAG) were used as a
control to validate RNA integrity, the reverse transcriptase reaction
and the polymerase chain reaction (PCR). PCR reactions
were cycled 35 times with a cycle profile of 1 min at 94°C, 2 min
at 50°C and 2 min at 72°C, using 0.2 units of SuperTaq
(HT/Biotechnology, Cambridge, UK) per reaction. Reaction prod-
ucts were analysed by agarose gel electrophoresis followed by
Southern blotting and hybridization with the corresponding rat
inhibin subunit cDNA probes (Esch et al, 1987), a rat ActRIIA
cDNA probe (de Winter et al, 1992) or a rat ActRIIB cDNA probe
(JG Wesseling, unpublished) corresponding to nucleotides
683-1147 (Feng et al, 1993). Activin type I receptorproducts were
hybridized with human ActRIA or ActRIB cDNA probes (ten
Dijke et al, 1993); follistatin and activin PC subunit PCR products
were detected using cloned human partial cDNAs (see below).
cDNA cloning
cDNAs encoding part ofthe human inhibin subunits, activin recep-
tors and follistatin were cloned after reverse transcriptase- poly-
merase chain reaction (RT-PCR) with AmpliTaq (Roche
Molecular Systems, Branchburg, NJ, USA). Human ActRIIA
(nucleotides 132-791; Donaldson et al, 1992) and inhibin f.A
subunit (nucleotides 309-946; Mason et al, 1986) cDNAs were
cloned from K562 cells; ActRIIB (nucleotides 429-947; Hilden
et al, 1994) and inhibin 1B subunit (nucleotides 263-1073; Mason
et al, 1986) cDNAs were cloned from human testis. The inhibin
ax-subunit cDNA (nucleotides 125-411; Mayo et al, 1986) was
cloned from genomic DNA, and follistatin cDNA (nucleotides
345-819; Shimasaki et al, 1988) was cloned from placental RNA.
For the activin PC subunit, a partial cDNA was cloned corre-
sponding to nucleotides 824-1240 (Hotten et al, 1995), using
PCR on K562 genomic DNA. All cDNAs were subcloned in
pBluescript KS(-) (Stratagene, La Jolla, CA, USA) and checked
by sequencing. For the activin type I receptors, a DraIIIXbaI frag-
ment (nucleotides 1261-1692; ten Dijke et al, 1993) of ActRIA
and an ApaI-ApaI fragment of ActRIB (nucleotides 73-361;
GenBank, accession number Z22536) were subcloned in
pBluescript KS(-).
RNAase protection assay
cDNA clones were digested with appropriate restriction enzymes
and 32P-labelled RNA probes were made by transcription in the
presence of [32P]UTP using T3 or T7 RNA polymerase
(Stratagene). The cRNA probes protect nucleotides 602-791 for
ActRIIA (Donaldson et al, 1992), nucleotides 631-947 for
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Figure 1 RNAase protection analyses of (A) activin receptors and (B) inhibin subunits and follistatin in germ cell tumours. Five micrograms of RNA was hybridized
with the probes indicated. Representative data for seminomas (SE), non-seminomas (NS) and spermatocytic seminomas (SP) are shown. Results were visualized
using a Phosphorlmager. Normal testis (NT) RNA served as a control. Actin signal is shown at a 100-fold decreased intensity compared with the other signals
ActRIIB (Hilden et al, 1994), nucleotides 126-411 for the inhibin
a-subunit (Mayo et al, 1986), nucleotides 702-946 for the inhibin
PA subunit (Mason et al, 1986), nucleotides 845-1073 for the
inhibin PB subunit (Mason et al, 1986) and nucleotides 508-819
for the follistatin transcript (Shimasaki et al, 1988). The ActRIA
probe protects nucleotides 1482-1692 (ten Dijke et al, 1993),
while the ActRIB probe corresponds to fragment 191-361
(GenBank, accession number Z22536). For human gamma actin, a
probe corresponding to nucleotides 1207-1337 (Erba et al, 1986)
was used. RNAase protection assays were performed as described
by Sambrook et al (1989). RNAase treatment was performed
using 100 U ml RNAase TI (Boehringer, Mannheim, Germany)
in combination with 10 jg ml-' RNAase A (Boehringer).
Hybridization temperature was 42°C. Routinely, 5 ,ug of RNA
was analysed. Results were quantified using a Phosphorlmager
(Molecular Dynamics/B&L Systems, Maarssen, The Netherlands)
and data are expressed relative to gamma actin. Mean values are
given ± s.e.m. and comparisons between groups were made using
the Mann-Whitney U-test; P-values lower than 0.05 were inter-
preted as the results being significantly different. Relationships
between various parameters were investigated on the basis of
linear regression.
RESULTS
Activin receptors
Total RNA was isolated from 20 human TGCTs and two spermato-
cytic seminomas. Initially, the expression of mRNAs coding for
activin type IA and IB and for activin receptors type IIA and IIB
was demonstrated by RT-PCR on RNA isolated from two semi-
nomas and two non-seminomas as described under Materials and
methods (results not shown). The presence of activin type I and
type II receptor transcripts was confirmed by RNAase protection
assays (Figure IA); transcription levels were quantified and
expressed relative to gamma actin (Figure 2). All four activin
receptors were detected in seminomas, non-seminomas and
spermatocytic seminomas. Seminomas contained significantly less
ActRIIA mRNA than non-seminomas [3.0 ± 0.4 vs 5.0 ± 0.7 rela-
tive units (RU) respectively; P < 0.05], whereas ActRIIB mRNA
expression levels were not different. RNAase protection assays
failed to detect expression ofActRIIB in one non-seminoma (MT).
The transcript levels for ActRIB mRNA in seminomas were signif-
icantly higher (P < 0.05) than those in non-seminomas (10.5 ± 2.0
vs 4.0 ± 0.9 RU respectively), while, in addition, a significant
difference was found for ActRIA (5.4 ± 1.1 vs 2.5 ± 0.9 RU
respectively; P < 0.05). RNAase protection assays failed to detect
expression of ActRIA in three non-seminomas (one embryonal
carcinoma and two mixed tumours). Expression levels in sperma-
tocytic seminomas were similar to those found in seminomas and
non-seminomas for ActRIA, while ActRIIB expression was
relatively high. ActRIB and ActRIIA mRNA expression levels
resembled those ofnon-seminomas.
Within seminomas or non-seminomas, significant correlations
were found between the expression ofActRIIA and type IA and IB
receptors: for seminomas r = 0.821 (P < 0.005) and r = 0.929
(P < 0.0005) respectively; for non-seminomas, r = 0.673 (P < 0.05)
and r = 0.533 (P < 0.05) respectively (Figure 3). In non-seminomas,
ActRIIB expression was significantly correlated with ActRIB
expression (r = 0.649; P < 0.025) (results not shown) but not with
ActRIA (r = 0.019).
Inhibin subunits and follistatin
Preliminary experiments using RT-PCR for inhibin subunits
revealed the presence of transcripts encoding both inhibin PA and
1B subunits but not inhibin a-subunit (results not shown).
Expression of the activin PC subunit, a recently cloned cDNA
showing close homology with the inhibin 3-subunits (Hotten et al,
1995), was found by RT-PCR in normal testis, while a weaker
signal was obtained in the two seminomas but not in the two non-
seminomas tested. RNAase protection assays performed on the 22
testicular tumours confirmed the presence of inhibin PA and 3B
subunit transcripts in seminomas and non-seminomas (Figure 1B).
Expression of the PA subunit transcript in the non-seminomas
ranged from 2.3 and 3.0 RU for one mature teratoma/yolk sac
tumours and the immature teratoma, respectively, to approxi-
mately 28 RU for one yolk sac tumour and one mixed tumour. The
expression levels in the non-seminomas were significantly
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Figure 2 Quantitative analysis of RNAase protection data for activin receptor expression in seminomas (SE), non-seminomas (NS) and spermatocytic
seminomas (SP). Signals of protected fragments were quantified using a Phosphorimager and are expressed in relative units (RU), normalized for actin. Normal
testis (NT) served as a control. The mean expression level for each group is indicated (-)
different from those found in the seminomas (14.8 ± 2.7 vs 1.3 +
0.2 RU respectively; P < 0.001) (Figure 4), while the spermato-
cytic seminomas showed PA subunit expression levels similar to
those in the seminomas. Inhibin PB subunit expression was found
in the seminomas, the non-seminomas and the spermatocytic semi-
nomas; mRNA levels did not significantly differbetween the semi-
nomas and the non-seminomas. RNAase protection assays for
activin PC subunit, using RNA from human liver as a positive
control, did not yield any signal in the tumours investigated
(results not shown). No inhibin a-subunit mRNA could be demon-
strated in the two spermatocytic seminomas, in 10 out of the 11
non-seminomas and in six out of the nine seminomas. Follistatin
was predominantly expressed in the non-seminomas (3.2 ± 0.6 vs
0.3 ± 0.3 RU in the seminomas; P < 0.05) and in the spermatocytic
seminomas.
Among the non-seminomas studied, one tumour (mature
teratoma/yolk sac tumour) showed a high expression ofinhibinPB
subunit mRNA (24.0 RU) in combination with a high expression
ofinhibin a-subunit mRNA (234 RU), suggesting that this tumour
may produce inhibin. This non-seminoma also expressed rela-
tively high levels of ActRIIA (10 units), ActRIA (10.3 units) and
ActRIB (9.0 units), while ActRIIB (8.9 units), inhibin ,BA subunit
(12.7 units) and follistatin (4.5 units) were similar to the average
values found in the non-seminomas.
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Figure 3 Correlation between ActRIA or ActRIB expression and ActRIIA mRNA levels in TGCTs. Separate regression lines were calculated for seminomas
(A) and non-seminomas (0). Data for spermatocytic seminomas (E) were included in the graph for reference
DISCUSSION
Autocrine stimulation of cell proliferation is a common theme in
cancer. Activin and inhibin have been implicated to be involved
in the regulation of normal spermatogenesis: inhibin reduces
spermatogonial numbers (van Dissel-Emiliani et al, 1989), while
activin stimulates the proliferation of spermatogonia in rat germ
cell-Sertoli cell co-cultures (Mather et al, 1990). Activin also
stimulates the proliferation of mouse P19 embryonal carcinoma
cells and it inhibits the retinoic acid-induced differentiation of
these cells (Hashimoto et al, 1990; van den Eijnden-van Raaij et al,
1991). Based upon these data, we hypothesized that activin may be
involved in germ cell tumour proliferation.
TGCTs are thought to originate from gonocytes that have
undergone malignant transformation (Skakkebxk et al, 1987;
Giwercman and Skakkebxk, 1993), but thus farthe factors involved
in this process are unknown. Apparently, these germ cell-derived
tumours, when invasive, are not under Sertoli cell control and have
the ability to survive without these nursing cells. This suggests that
the tumours have acquired means to produce additional factors
necessary for proliferation and survival. In the present study, we
have shown that tumours originating from germ cells express
activin type I and activin type II receptors, suggesting responsive-
ness to activin. These data are in agreement with the reported
expression of activin type II receptors in normal germ cells (de
Winter et al, 1992; Kaipia et al, 1993; Cameron et al, 1994) and in
the human teratocarcinoma cell line Tera-2 (de Jong et al, 1993;
RHN van Schaik, unpublished results). Our inability to detect
ActRIIB expression in one non-seminoma, a mature teratoma, is in
line with the down-regulation ofActRIIB mRNA levels when Tera-
2 cells are differentiated by retinoic acid (de Jong et al, 1993).
Significant differences were found between the expression of
ActRIA, ActRIB and ActRIIA in seminomas and non-seminomas,
giving rise to different ActRIA/ActRIB and ActRIIA/ActRIIB
receptor transcript ratios in these tumours. In the embryonal carci-
noma and in two mixed tumours, ActRIA mRNA levels could not
be detected by RNAase protection analysis. As differences in
affinity for activin (Attisano et al, 1992) and inhibin (Martens et al,
1997) have been reported for the type II receptors, and as the
biological response to activin depends on the type I receptor
involved in the type 11-type I receptor complex (Caircamo et al,
1994), the different receptor mRNA ratios found may indicate
differences between the tumours in their response to activin.
An important issue in activin research is the regulation of
receptor expression and the question of whether there is a prefer-
ence for interaction between a specific type I and type II receptor.
For this reason, we looked at correlations between expression of
activin receptors. ActRIA and ActRIB expression both correlated
with ActRIIA expression in seminomas and non-seminomas,
suggesting that expression of these transcripts may depend on
common factors in these tumours. Interestingly, the slopes of
the regression lines for seminomas and non-seminomas differ.
Possibly, the histologically heterogeneous non-seminomas contain
cell types with a different activin type I-type II receptor ratio.
Results ofin situ hybridization may resolve this point.
Inhibin PA and PB subunit mRNA expression in the normal
testis is restricted to Sertoli and peritubularmyoidcells and has not
been described in germ cells. The expression of these subunits in
all tumours of deranged germ cells investigated, i.e. TGCTs and
spernatocytic seminomas, suggests that these tumours have
acquired the potential to produce activin and may therefore indi-
cate the existence of an autocrine system for activin. This is espe-
cially the case in the more aggressive non-seminomas, which were
shown to express relatively high levels of inhibin PA subunit
mRNA. The recently described cloning of the activin PC subunit
cDNA (Hotten et al, 1995), which showed homology to the inhibin
PA and ,B subunits, prompted us to examine its expression in
TGCTs. Using activin PC subunit-specific primers, followed by
identification of the reaction products by hybridization with a
32P-labelled human activin PC subunit probe, we found signal in
normal testis and a weaker signal in the two seminomas analysed.
This expression in the normal testis is in agreement with a recent
report on rattestis, in which a 1.8-kb mRNA for activinPC mRNA
was found on a Northern blot containing poly(A)+ RNA of round
spermatids (Loveland et al, 1996). However, we were unable to
detect activin PC subunit mRNA in the normal human testis by
RNAase protection using conditions in which human liver gives a
positive signal. This indicates that the expression level for activin
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Figure 4 Quantitative analysis of RNAase protection data for inhibin a- and ,B-subunits and follistatin expression in seminomas (SE), non-seminomas (NS) and
spermatocytic seminomas (SP). Signals of protected fragments were quantified using a Phosphorimager and are expressed in relative units (RU), normalized
for actin. Normal testis (NT) served as a control. The mean expression level for each group is indicated (-)
P1C subunit in the testis is substantially lower than in the liver. This
is in agreement with the absence of an activin PC signal in a
Northern blot of adult mouse tissues (Lau et al, 1996). Therefore,
the absence of an activin ,BC subunit signal in the RNAase protec-
tion for the TGCTs led us to conclude that activin PC is not
expressed in substantial amounts in these tumours.
The combined expression of inhibin a- and jB subunit expres-
sion in one non-seminoma may be the result of extra-embryonal
differentiation, because expression of these subunits has been
described in trophoblastic cells and fetal membranes (Qu and
Thomas, 1995). Apparently, this is not a general phenomenon as
the other mature teratoma/yolk sac tumour in our panel did not
give rise to relatively high expression levels for inhibin a- and fiB
subunits; in addition, pure yolk sac or mature teratoma tumours
were negative for inhibin a-subunit mRNA. Evidence for inhibin
immunoreactivity in homogenates of non-seminomas has been
presented earlier (de Jong et al, 1990), indicating that inhibin
synthesis can occur in non-seminomas. As n-subunit expression is
found in all tumours investigated so far, while inhibin a-subunit is
expressed in only a few, one could speculate that a-subunit
synthesis occurs at a later stage in the development of some
tumours, thereby affecting activin-induced differentiation
processes. More research is necessary to elucidate the interplay
between inhibin and activin in TGCT differentiation processes.
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Expression of the activin-binding protein follistatin, like the
inhibin PA-subunit mRNA, was observed predominantly in non-
seminomas. In cultured rat pituitary cells, activin was found to
stimulate follistatin production (Bilezikjian et al, 1993), which is
thought to be an effect of activin on follistatin mRNA levels
(DePaolo et al, 1993). However, the correlations between follis-
tatin and inhibin PA mRNA expression (r = 0.457), follistatin and
inhibin fB mRNA (r = 0.040) or between follistatin and inhibin
(PA + fB) mRNA (r = 0.346) did not reach statistical significance
(P> 0.05). As the production of follistatin will inhibit activin
action, and thus interfere with the correlation between expression
of 3-subunits and biologically active activin, the described
approach is probably too simplistic to identify effects ofactivin on
follistatin expression in TGCTs. In seminomas, follistatin expres-
sion was at the detection limit of our assay, except for one tumour
in which follistatin mRNA levels exceeded the average expression
level found in the other seminomas by almost a factor of 10. This
tumour also differed from the other seminomas for mRNA levels
for activin type I and type II receptors which were a factor of4-12
lower than the average for seminomas; in addition, expression of
inhibin PA and fB subunits was substantially lower. Retrospective
investigation showed that this tumour was strongly vimentin
positive and therefore differed from the classical seminoma. We
are not aware to date, however, of any differences in clinical
behaviour between vimentin-positive and classical seminomas.
Indications for the presence of biologically active activin in
TGCTs are at present only indirect. Expression of the tyrosine
kinase c-kit was reported in 80% of seminomas, but only in 7%
of non-seminomas (Strohmeyer et al, 1991). Because it was
shown that c-kit mRNA expression in mouse erythroleukaemia
cells can be down-regulated by activin (Hino et al, 1995), these
observations are in line with higher bioactive activin levels
in non-seminomas compared with seminomas. Secondly, the
mRNA expression of hGDF-3, which can be stimulated by
activin in the human embryonal carcinoma-derived Tera-2 cells,
was significantly higher in non-seminomas than in seminomas
(Caricasole et al, submitted).
As activin receptors, inhibin subunits and follistatin are
expressed in germ cell tumours, activin may be involved in testic-
ular germ cell tumour development. Because CIS is found at sites
normally occupied by spermatogonia (Skakkebak et al, 1987),
these sites are likely to provide the specialized conditions required
for their survival and proliferation. Based upon our results, we
hypothesize that activin synthesis provides autocrine/paracrine
conditions for tumour progression, making the germ cell neoplasms
independent from Sertoli cell-secreted factors. The relatively high
expression of inhibin PA subunit mRNA in non-seminomas
compared with seminomas may thus be related to the higher
malignant potential of these TGCTs (Oosterhuis et al, 1993).
Interestingly, the spermatocytic seminomas that we included in our
study also expressed inhibin 3-subunits, indicating that activin
production may in general be favourable for autonomously prolifer-
ating germ cells. Because of the very low incidence rate of these
neoplasms, we were unable to investigate additional tumours. The
observed differences between seminomas and non-seminomas
further raise the question of whether these differences precede the
development of CIS into non-seminomas or seminomas or are
merely the result of this process. As activin expression is present
during mouse embryonal development (Albano et al, 1993; Feijen
et al, 1994), the increased activin mRNA expression found in non-
seminomas compared with seminomas could also be the result of
the malignant gonocytes acquiring pluripotency and entering
differentiation. In that case, the extent of activin synthesis by a
non-seminoma may determine the differentiation status of the
tumour, thereby affecting tumour progression and prognosis,
as a high percentage of embryonal carcinoma is prognostically
unfavourable (Moul et al, 1994). Additional research to elucidate
expression of inhibin subunits, activin receptors and follistatin in
the different tumour components of non-seminomas by in situ
hybridization and immunohistochemistry are currently being
undertaken to elucidate these aspects.
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